CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2023-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2023 financial results for the period ended June 30, 2023 . “We were excited to see the announcement from Ipsen that the U.S.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2023-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023 . “During the first quarter of 2023 our operating expenses remained
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2023-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022 . “We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 5, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has extended the Section 382 net operating loss rights plan (the “ Plan ”) that was adopted in 2019.
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) issued a press release today reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 3, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2022 financial results for the period ended September 30, 2022 . “During the third quarter we continued to see the benefits of reduced
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2022 financial results for the period ended June 30, 2022 . “We are pleased to report continued reductions in operating expenses as
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 5, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 31, 2022 . “During the first quarter of 2022 we continued to see reductions in our
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2021 financial results for the period ended December 31, 2021 . “During 2021 we have continued to reduce our operating expenses and remain
